Allurion Technologies, Inc. (ALUR) recently announced the submission of the first three modules of its premarket approval application (PMA) to the FDA for the Allurion Balloon.Allurion capitalized on the opportunity provided by the FDA's modular submission program to improve the efficiency of the application process. The company expects to file the fourth and final module of the PMA, containing the clinical data from its AUDACITY trial, early next year.Likely Trend of ALUR Stock Following the NewsFollowing ...